NetWorth
LeaderPortfolio
Repik
Alexey Repik
Rank #1696
RUSSIA•Healthcare•Pharmaceuticals

Alexey Repik

Net Worth
$2.424B
0% (24h)
Alexey Repik is a prominent Russian businessman and public figure, recognized as a leader in the healthcare industry. Born in Moscow in 1979, Repik is the founder of R-Pharm, one of Russia's largest pharmaceutical companies. His career, which began in 1995, has been marked by significant achievements, including the establishment of high-quality, local drug production and strategic partnerships with global pharmaceutical companies. As of March 2026, his estimated net worth is $2.4 billion. Repik also serves as Chairman of the All-Russian public organization "Business Russia" and is known for his philanthropic initiatives.

How to read Alexey Repik's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Alexey Repik, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.424B alongside global rank #1696, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (RUSSIA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Alexey Repik was born on August 27, 1979, in Moscow, Russia. He graduated from the Higher School of Economics in 2003 with a degree in economics and enterprise management. During his studies, he worked as an economist in a city hospital, which gave him insights into the healthcare sector.

Rise to Success

Repik's career in healthcare began in 1995. He founded R-Pharm in 2001, with an initial investment of $40,000. R-Pharm quickly became a major player in the pharmaceutical market, and Repik expanded the company by establishing branches across Russia. In 2017, Mitsui & Co., Ltd. acquired a 10% share of R-Pharm for $200 million. Repik's company was involved in the production of a vaccine against COVID-19 for AstraZeneca.

Key Business Strategies

A key strategy for R-Pharm was the establishment of high-quality, local drug production in Russia, which helped to reduce the country's reliance on imports. R-Pharm formed strategic partnerships with leading global pharmaceutical companies, including Pfizer, Bayer, and Sanofi. Repik also focused on research and development, particularly in oncology, immunology, and rare diseases, positioning R-Pharm as an innovative company.

Philanthropy

Repik is involved in philanthropy. He is donating for construction of a large shelter for 1,500 dogs per year in Yaroslavl, a city 250 kilometers from Moscow. He also co-founded the fund "Utoli Moya Pechali" with the Russian Orthodox Church, providing assistance to hospitals, orphans, and children from low-income families, as well as people with disabilities.

Career Timeline

2019

Chairman of Business Russia

Became Chairman of the All-Russian public organization "Business Russia".

2017

Mitsui Investment

Mitsui & Co., Ltd. acquired a 10% shares of R-Pharm for $200 million.

2014

President of Delovaya Rossiya

Became the President of the Russian Business Association 'Delovaya Rossiya'.

2001

Founded R-Pharm

Established R-Pharm, a Russian pharmaceutical company.

Philanthropic Impact

Animal WelfareUndisclosed

Dog Shelter

Donating for construction of a large shelter for 1,500 dogs per year in Yaroslavl, a city 250 kilometers from Moscow.

Social WelfareUndisclosed

Fund 'Utoli Moya Pechali'

Providing assistance to hospitals, orphans, and children from low-income families, as well as people with disabilities.

Net Worth History

In-Depth Analysis

Early Life and Education

Alexey Repik was born on August 27, 1979, in Moscow, Russia. He graduated from the Higher School of Economics in 2003 with a degree in economics and enterprise management. During his studies, he worked as an economist in a city hospital, which gave him insights into the healthcare sector.

Rise to Success

Repik's career in healthcare began in 1995. He founded R-Pharm in 2001, with an initial investment of $40,000. R-Pharm quickly became a major player in the pharmaceutical market, and Repik expanded the company by establishing branches across Russia. In 2017, Mitsui & Co., Ltd. acquired a 10% share of R-Pharm for $200 million. Repik's company was involved in the production of a vaccine against COVID-19 for AstraZeneca.

Key Business Strategies

A key strategy for R-Pharm was the establishment of high-quality, local drug production in Russia, which helped to reduce the country's reliance on imports. R-Pharm formed strategic partnerships with leading global pharmaceutical companies, including Pfizer, Bayer, and Sanofi. Repik also focused on research and development, particularly in oncology, immunology, and rare diseases, positioning R-Pharm as an innovative company.

Philanthropy

Repik is involved in philanthropy. He is donating for construction of a large shelter for 1,500 dogs per year in Yaroslavl, a city 250 kilometers from Moscow. He also co-founded the fund "Utoli Moya Pechali" with the Russian Orthodox Church, providing assistance to hospitals, orphans, and children from low-income families, as well as people with disabilities.

Data Sources & Methodology

Figures for Alexey Repik are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom